Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness M, Kenney J, Reiss M, Lacy J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Research 2000, 60: 5354-8. PMID: 11034070.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusPosttransplant lymphoproliferative disorderLymphoproliferative disordersBcl-2 antisenseLymphoproliferative diseaseImmunodeficient miceEpstein-Barr virus-associated lymphoproliferative diseaseBcl-2EBV-positive lymphoproliferative diseaseSequence-dependent antitumor effectsMajority of EBVAntisense oligodeoxynucleotide therapyEBV-positive malignanciesB-cell lymphoproliferationBcl-2 antisense therapyInhibition of proliferationLymphoblastoid B cellsTreatment strategiesChemoprotective effectsAntitumor effectsVitro treatmentB cellsChimeric modelDecreased expressionRational target